INMB Q1 2024 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14,000-63.2% YoY

Gross Profit

$14,000100.0% margin

Operating Income

-$11M-78692.9% margin

Net Income

-$11M-78750.0% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

-50.0%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$47M

Total Liabilities

$18M

Stockholders' Equity

$29M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14,000	$38,000	-63.2%
Gross Profit	$14,000	$38,000	-63.2%
Operating Income	-$11M	-$6M	-71.5%
Net Income	-$11M	-$7M	-68.7%